vs
JELD-WEN Holding, Inc.（JELD）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
JELD-WEN Holding, Inc.的季度营收约是Revvity的1.0倍（$802.0M vs $772.1M），Revvity净利率更高（12.7% vs -5.2%，领先18.0%），Revvity同比增速更快（5.9% vs -10.5%），Revvity自由现金流更多（$161.8M vs $3.4M），过去两年Revvity的营收复合增速更高（9.0% vs -8.6%）
JELD-WEN是一家总部位于美国北卡罗来纳州夏洛特的企业，在全球19个国家运营着超过120家生产基地。公司主营设计、生产并销售室内外门窗、各类材质窗品、墙体系统、淋浴隔断、衣帽间系统等建筑部件，产品广泛应用于住宅与非住宅建筑的新建、维修及改造工程。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
JELD vs RVTY — 直观对比
营收规模更大
JELD
是对方的1.0倍
$772.1M
营收增速更快
RVTY
高出16.3%
-10.5%
净利率更高
RVTY
高出18.0%
-5.2%
自由现金流更多
RVTY
多$158.4M
$3.4M
两年增速更快
RVTY
近两年复合增速
-8.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $802.0M | $772.1M |
| 净利润 | $-41.9M | $98.4M |
| 毛利率 | 14.7% | — |
| 营业利润率 | -1.8% | 14.5% |
| 净利率 | -5.2% | 12.7% |
| 营收同比 | -10.5% | 5.9% |
| 净利润同比 | 38.7% | 3.9% |
| 每股收益（稀释后） | $-0.50 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JELDRVTY
| Q4 25 | $802.0M | $772.1M | ||
| Q3 25 | $809.5M | $698.9M | ||
| Q2 25 | $823.7M | $720.3M | ||
| Q1 25 | $776.0M | $664.8M | ||
| Q4 24 | $895.7M | $729.4M | ||
| Q3 24 | $934.7M | $684.0M | ||
| Q2 24 | $986.0M | $691.7M | ||
| Q1 24 | $959.1M | $649.9M |
净利润JELDRVTY
| Q4 25 | $-41.9M | $98.4M | ||
| Q3 25 | $-367.6M | $46.7M | ||
| Q2 25 | $-21.5M | $53.9M | ||
| Q1 25 | $-190.1M | $42.2M | ||
| Q4 24 | $-68.4M | $94.6M | ||
| Q3 24 | $-74.4M | $94.4M | ||
| Q2 24 | $-18.5M | $55.4M | ||
| Q1 24 | $-27.7M | $26.0M |
毛利率JELDRVTY
| Q4 25 | 14.7% | — | ||
| Q3 25 | 17.4% | 53.6% | ||
| Q2 25 | 17.4% | 54.5% | ||
| Q1 25 | 14.4% | 56.5% | ||
| Q4 24 | 16.4% | — | ||
| Q3 24 | 19.2% | 56.3% | ||
| Q2 24 | 19.3% | 55.7% | ||
| Q1 24 | 18.0% | 54.6% |
营业利润率JELDRVTY
| Q4 25 | -1.8% | 14.5% | ||
| Q3 25 | -25.0% | 11.7% | ||
| Q2 25 | -1.7% | 12.6% | ||
| Q1 25 | -23.8% | 10.9% | ||
| Q4 24 | -5.7% | 16.3% | ||
| Q3 24 | -5.6% | 14.3% | ||
| Q2 24 | 0.5% | 12.4% | ||
| Q1 24 | -2.9% | 6.8% |
净利率JELDRVTY
| Q4 25 | -5.2% | 12.7% | ||
| Q3 25 | -45.4% | 6.7% | ||
| Q2 25 | -2.6% | 7.5% | ||
| Q1 25 | -24.5% | 6.4% | ||
| Q4 24 | -7.6% | 13.0% | ||
| Q3 24 | -8.0% | 13.8% | ||
| Q2 24 | -1.9% | 8.0% | ||
| Q1 24 | -2.9% | 4.0% |
每股收益（稀释后）JELDRVTY
| Q4 25 | $-0.50 | $0.86 | ||
| Q3 25 | $-4.30 | $0.40 | ||
| Q2 25 | $-0.25 | $0.46 | ||
| Q1 25 | $-2.24 | $0.35 | ||
| Q4 24 | $-0.80 | $0.77 | ||
| Q3 24 | $-0.88 | $0.77 | ||
| Q2 24 | $-0.22 | $0.45 | ||
| Q1 24 | $-0.32 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $136.1M | $919.9M |
| 总债务越低越好 | $1.1B | — |
| 股东权益账面价值 | $92.2M | $7.3B |
| 总资产 | $2.1B | $12.2B |
| 负债/权益比越低杠杆越低 | 12.47× | — |
8季度趋势，按日历期对齐
现金及短期投资JELDRVTY
| Q4 25 | $136.1M | $919.9M | ||
| Q3 25 | $106.7M | $931.4M | ||
| Q2 25 | $134.1M | $991.8M | ||
| Q1 25 | $132.5M | $1.1B | ||
| Q4 24 | $150.3M | $1.2B | ||
| Q3 24 | $208.5M | $1.2B | ||
| Q2 24 | $212.8M | $2.0B | ||
| Q1 24 | $234.5M | $1.7B |
总债务JELDRVTY
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
股东权益JELDRVTY
| Q4 25 | $92.2M | $7.3B | ||
| Q3 25 | $113.9M | $7.4B | ||
| Q2 25 | $477.1M | $7.6B | ||
| Q1 25 | $452.1M | $7.6B | ||
| Q4 24 | $620.1M | $7.7B | ||
| Q3 24 | $720.3M | $7.9B | ||
| Q2 24 | $770.0M | $7.9B | ||
| Q1 24 | $811.5M | $7.8B |
总资产JELDRVTY
| Q4 25 | $2.1B | $12.2B | ||
| Q3 25 | $2.2B | $12.1B | ||
| Q2 25 | $2.5B | $12.4B | ||
| Q1 25 | $2.4B | $12.4B | ||
| Q4 24 | $2.6B | $12.4B | ||
| Q3 24 | $2.8B | $12.8B | ||
| Q2 24 | $2.9B | $13.4B | ||
| Q1 24 | $2.9B | $13.4B |
负债/权益比JELDRVTY
| Q4 25 | 12.47× | — | ||
| Q3 25 | 10.14× | — | ||
| Q2 25 | 2.42× | — | ||
| Q1 25 | 2.56× | — | ||
| Q4 24 | 1.86× | — | ||
| Q3 24 | 1.64× | — | ||
| Q2 24 | 1.53× | — | ||
| Q1 24 | 1.46× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $3.4M | $161.8M |
| 自由现金流率自由现金流/营收 | 0.4% | 21.0% |
| 资本支出强度资本支出/营收 | 3.7% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-124.6M | $509.4M |
8季度趋势，按日历期对齐
经营现金流JELDRVTY
| Q4 25 | $32.8M | $182.0M | ||
| Q3 25 | $11.2M | $138.5M | ||
| Q2 25 | $34.6M | $134.3M | ||
| Q1 25 | $-83.5M | $128.2M | ||
| Q4 24 | $28.2M | $174.2M | ||
| Q3 24 | $37.6M | $147.9M | ||
| Q2 24 | $51.4M | $158.6M | ||
| Q1 24 | $-11.0M | $147.6M |
自由现金流JELDRVTY
| Q4 25 | $3.4M | $161.8M | ||
| Q3 25 | $-13.1M | $120.0M | ||
| Q2 25 | $5.3M | $115.5M | ||
| Q1 25 | $-120.3M | $112.2M | ||
| Q4 24 | $-23.9M | $149.8M | ||
| Q3 24 | $-4.3M | $125.6M | ||
| Q2 24 | $14.7M | $136.6M | ||
| Q1 24 | $-42.2M | $129.7M |
自由现金流率JELDRVTY
| Q4 25 | 0.4% | 21.0% | ||
| Q3 25 | -1.6% | 17.2% | ||
| Q2 25 | 0.6% | 16.0% | ||
| Q1 25 | -15.5% | 16.9% | ||
| Q4 24 | -2.7% | 20.5% | ||
| Q3 24 | -0.5% | 18.4% | ||
| Q2 24 | 1.5% | 19.7% | ||
| Q1 24 | -4.4% | 20.0% |
资本支出强度JELDRVTY
| Q4 25 | 3.7% | 2.6% | ||
| Q3 25 | 3.0% | 2.6% | ||
| Q2 25 | 3.6% | 2.6% | ||
| Q1 25 | 4.7% | 2.4% | ||
| Q4 24 | 5.8% | 3.4% | ||
| Q3 24 | 4.5% | 3.3% | ||
| Q2 24 | 3.7% | 3.2% | ||
| Q1 24 | 3.3% | 2.7% |
现金转化率JELDRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JELD
| North America Segment | $522.0M | 65% |
| Europe Segment | $280.0M | 35% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
